Cystinosis Clinical Trial
Official title:
Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis
Background:
-(Degree)ystinosis is an inherited disease. If not treated correctly, it can cause muscle
wasting and weakness and kidney damage. Researchers want to learn if growth hormone (GH) can
help people with cystinosis.
Objective:
- To learn if GH treatment can slow or reverse muscle wasting and improve muscle strength in
people with cystinosis.
Eligibility:
- People 18 and older who are already enrolled in protocol 78-HG-0093.
Design:
- Participants will be admitted to the clinic for eight 3 4 day visits, mostly four months
apart.
- At each visit, participants will have a history and physical exam and give urine and
blood samples.
- At month 0 or 13, participants will take tests that will be repeated at their 12- or
25-month visit:
- They will have an eye exam, medical consultations, and strength and movement tests.
- They will complete questionnaires.
- They may have tests of heart activity and lung function.
- They will have ultrasound imaging of their arm and hand muscles. They will have a scan
of their legs while lying in a magnetic resonance imaging machine (a big metal
cylinder). They will have a DEXA bone scan (two X-ray beams measure body composition).
They will also swallow barium while X-ray imaging records the throat muscles.
- Participants will be randomly assigned to either receive or not receive GH for the first
12 months. Then, at month 13, if they received GH, they will switch for the next 12
months.
- Participants will take GH as a daily injection. They will be taught how to give the
injections.
Cystinosis is an autosomal recessive storage disorder due to defective transport of the amino
acid cystine out of cellular lysosomes. Cystine accumulation leads to cellular dysfunction in
most of organs and tissues. Available treatment with the cystine-depleting agent, cysteamine,
can prevent or delay organ damage, including that of muscles. In poorly treated patients,
however, a progressive vacuolar myopathy with muscle wasting beginning in the second decade
of life significantly debilitates some patients. Muscle biopsy demonstrates prominent
unrimmed vacuoles with small ring fibers but no evidence of endomysial inflammation. Plasma
and muscle carnitine deficiency, impairing mitochondrial fatty acid metabolism, might also
limit muscle energy production. Growth Hormone (GH) can potentially counter the muscle
wasting of cystinosis patients. It has consistently induced anabolic effects in patients in
malnourished or catabolic states, by enhancing the growth and development of bone, connective
tissue, viscera, fat, and musculoskeletal muscles. GH, at doses of approximately 0.006 to 0.1
mg/kg/day, has proven safe and effective in HIV/AIDS wasting, parenteral nutrition-dependent
short bowel syndrome, pediatric chronic kidney disease, and adult and pediatric GH-deficiency
states. The current protocol is a randomized (to treatment or no treatment) crossover
clinical trial to determine if GH (0.03 mg/kg/day) is beneficial for muscle wasting in
cystinosis. Patients are examined at the NIH Clinical Research Center every 4 months for 2
years. Change in muscle mass will serve as the primary outcome parameter, and rhGH
(Humatrope) will be provided by Eli Lilly. HumatropeR (somatropin) is currently approved by
the FDA for:
- Treatment of children with short stature or growth failure associated with growth
hormone (GH) deficiency, Turner syndrome, idiopathic short stature, SHOX deficiency, and
failure to catch up in height after small for gestational age birth.
- Treatment of adults with either childhood-onset or adult-onset GH deficiency.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05545774 -
Neuromuscular Characterisation in Late Adolescent and Adult Cystinosis Patients
|
||
Completed |
NCT01432561 -
Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagonâ„¢
|
N/A | |
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Completed |
NCT04125927 -
Cystadrops in Pediatric Cystinosis Patients From Six Months to Less Than Two Years Old (SCOB2)
|
Phase 3 | |
Completed |
NCT00071903 -
The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study
|
N/A | |
Recruiting |
NCT05994534 -
PK and PD Study of NPI-001 and Cysteamine Bitartrate
|
Phase 1/Phase 2 | |
Completed |
NCT00004312 -
Establishment of a Database for Long-Term Monitoring of Patients With Nephropathic Cystinosis
|
N/A | |
Completed |
NCT00004350 -
Evaluation of Fanconi Syndrome and Cystinosis
|
N/A | |
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Completed |
NCT02533076 -
The Functional Consequences of the CTNS-deletion for the TRPV1-receptor in Cystinosis Patients
|
Phase 0 | |
Enrolling by invitation |
NCT05146830 -
A Long-Term Follow-Up Study of Participants With Cystinosis Who Previously Received CTNS-RD-04
|
||
Completed |
NCT00872729 -
Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis
|
Phase 1/Phase 2 | |
Completed |
NCT00001736 -
New Cysteamine Eye Drops Formulation to Treat Corneal Crystals in Cystinosis
|
Phase 1 | |
Recruiting |
NCT05959668 -
Development of Health-related Quality of Life Instrument for Patients With Cystinosis
|
||
Completed |
NCT01614431 -
N Acetyl Cysteine for Cystinosis Patients
|
Phase 4 | |
Recruiting |
NCT05843851 -
Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria
|
N/A | |
Completed |
NCT01000961 -
Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis
|
Phase 3 | |
Active, not recruiting |
NCT03897361 -
Stem Cell Gene Therapy for Cystinosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|